The research, led by Sharon J. Elliot and Marilyn K. Glassberg of Loyola University Chicago Stritch School of Medicine, together with colleagues including Arthur P. Arnold of UCLA, one of the pioneers of modern sex-differences biology, set out to dissect a problem that has frustrated the field for decades. Epidemiological data consistently show that idiopathic pulmonary fibrosis, or IPF, is more common, more aggressive, and more lethal in men. Yet for years, researchers attempting to explain this disparity could only compare males and females as whole biological units. In such comparisons, hormones and chromosomes travel together, inseparable, making it nearly impossible to determine which factor drives disease susceptibility. The new study breaks that confound apart using an elegant genetic tool known as the Four Core Genotypes mouse model.

The Four Core Genotypes model is deceptively simple in concept but powerful in execution. By shuffling the sex-determining Sry gene onto an autosome, researchers generate four distinct groups of mice: animals with XX chromosomes that develop ovaries, XX animals with testes, XY animals with ovaries, and XY animals with testes. This arrangement uncouples gonadal sex, the source of circulating estrogen and testosterone, from sex chromosome complement. Any difference in disease outcome between XX and XY animals must, by definition, be chromosomal in origin, while differences between animals with ovaries and testes point to hormonal mechanisms. When the two axes interact, the model exposes that too.

In this study, the team worked with aged mice, a crucial design choice given that IPF is overwhelmingly a disease of later life, typically striking people in their sixties and seventies. The animals were subjected to bleomycin-induced lung injury, a standard laboratory model in which a chemotherapeutic agent triggers inflammation and subsequent fibrosis that mimics key features of human IPF. The researchers then assessed fibrosis severity through multiple independent measures: histological scoring of scarred tissue, quantification of collagen deposition, and profiling of profibrotic gene expression. They also examined a battery of molecular players implicated in fibrotic remodeling, including estrogen receptor alpha and beta signaling, matrix metalloproteinase activity, insulin-like growth factor-1, and a panel of regulatory microRNAs. Statistical analysis relied on two-way analysis of variance to formally separate the effects of gonadal sex, sex chromosome complement, and their interaction, with gonadectomy experiments analyzed by three-way ANOVA to incorporate hormone status as a third variable.

The results were striking. The most severe fibrosis appeared not in typical males, as one might naively predict, but in XY mice with ovaries, animals carrying the male chromosome complement without any exposure to male gonadal hormones. This unexpected finding carries a profound implication: the Y chromosome, or some dosage effect tied to the XY complement, actively increases susceptibility to lung scarring even in the absence of testosterone. Alongside the worsening fibrosis in these animals, the researchers observed elevated expression of estrogen receptor alpha and an increased ratio of ER alpha to ER beta, a shift previously associated with profibrotic signaling in other organ systems.

At the opposite pole, XX mice with testes showed the mildest fibrotic response, and this protection correlated with the highest expression of estrogen receptor beta. ER beta has increasingly been viewed as the protective sibling in the estrogen receptor family, counterbalancing the remodeling signals driven by ER alpha. The inverse relationship between the ER alpha-to-ER beta ratio and fibrosis severity across the genotypes suggests that the balance between these two receptor isoforms functions as a molecular dial tuning the lung’s wound-healing response, and that chromosomal context helps set that dial.

The study went further than simply assigning blame to chromosomes or hormones. By surgically removing the gonads in subsets of animals, the researchers could distinguish between organizational effects, the long-lasting developmental programming imposed by hormones early in life, and activational effects, the ongoing day-to-day influence of circulating hormones in adulthood. The gonadectomy experiments revealed both types of effects at work, and, critically, uncovered genuine three-way interactions among gonadal sex, sex chromosomes, and hormone status. In other words, the severity of lung injury after hormone removal depended on the animal’s chromosome makeup, a finding that no simple hormone-centered model could have predicted. Fibrotic pathways across the lung were regulated by gonadal sex, by sex chromosome complement, and often by the interplay of both.

Adding a layer of mechanistic depth, the team identified sex chromosome-dependent regulation of two microRNAs with well-established links to fibrosis: let-7d and miR-29a. Both have antifibrotic credentials, with miR-29a in particular known to suppress collagen expression. In the new study, their expression levels varied with chromosomal dosage, tying the XY or XX complement directly to the ER alpha and IGF-1 mediated remodeling pathways that drive scar formation. This provides a plausible molecular bridge between chromosomes and tissue pathology: chromosomes influence microRNA expression, microRNAs modulate receptor and growth factor signaling, and those signals choreograph the deposition of collagen that stiffens and destroys lung tissue.

For a disease as devastating as IPF, these insights arrive at a moment of genuine need. IPF affects an estimated several million people worldwide, with median survival after diagnosis historically measured in just a few years. The only approved drug therapies, antifibrotic agents such as pirfenidone and nintedanib, slow disease progression but do not reverse it, and lung transplantation remains the sole definitive option. The new work suggests that the search for better treatments has been conducted, in effect, with one hand tied behind the back, because preclinical research has often relied on male-only animal models or has failed to account for sex as a biological variable. If the mechanisms of fibrosis differ between XX and XY lungs, as this study demonstrates, then therapies tested only in one sex may perform very differently in the other.

The clinical implications cut in several directions. For men, whose disease risk appears chromosomally encoded, targeting downstream profibrotic signaling such as the ER alpha–IGF-1 axis may hold particular promise. For women, who are not immune to IPF and in whom the disease may be underdiagnosed, the protective role of ER beta suggests that selectively activating that receptor could someday be a viable antifibrotic strategy. The finding that hormones leave organizational imprints that persist into old age also raises questions about whether lifetime hormone exposure, including the timing of puberty, pregnancy, or menopause, shapes individual fibrosis risk decades later, a hypothesis the authors suggest is ripe for future investigation.

The study also carries methodological weight for the broader biomedical enterprise. Funding agencies and journals increasingly mandate that researchers consider sex as a biological variable, yet most studies still treat sex as a binary demographic label rather than a mechanistic factor. The Four Core Genotypes approach, deployed here in a disease model that mirrors a human condition with one of the most dramatic sex skews in medicine, offers a template for how to move beyond catalogs of sex differences and toward causal, mechanistic explanations. The fact that the greatest susceptibility appeared in the genotype least represented in any conventional study, XY animals with ovaries, is itself a lesson in how much such designs can miss.

The work, supported by the National Institute on Aging and Loyola University of Chicago development funds, was published as an open-access article, reflecting the authors’ evident intent that the discovery reach clinicians, sex-differences biologists, and pulmonologists alike. It remains early-stage research conducted in mice, and the leap from bleomycin-injured rodents to human patients with IPF is a long one. But the direction it provides is concrete: screen candidate antifibrotic drugs in both chromosomal contexts, watch the ER alpha-to-ER beta balance, and pay attention to microRNAs like let-7d and miR-29a as both biomarkers and therapeutic levers.

For the men who develop IPF at rates their sisters and wives never will, the study offers something the field has lacked: a mechanistic account of why. The scarring difference is not an accident of anatomy or lifestyle. It is rooted in the dosage of genes on the sex chromosomes, modulated across a lifetime by the hormones those chromosomes direct, and executed in the lung through a network of receptors, growth factors, and microRNAs that can now be named, studied, and, perhaps, blocked. In the effort to tame pulmonary fibrosis, sex is no longer a confounder to be averaged away. It is the map.